



(86) Date de dépôt PCT/PCT Filing Date: 1995/01/06
 (87) Date publication PCT/PCT Publication Date: 1995/07/13
 (45) Date de délivrance/Issue Date: 2010/05/11
 (85) Entrée phase nationale/National Entry: 1996/07/10
 (86) N° demande PCT/PCT Application No.: BE 1995/000002
 (87) N° publication PCT/PCT Publication No.: 1995/018861
 (30) Priorités/Priorities: 1994/01/11 (NL9400045);
 1994/01/24 (EP94200159.5)

(51) Cl.Int./Int.Cl. *C12N 15/56* (2006.01),
A61K 39/145 (2006.01), *C07K 14/11* (2006.01),
C12N 15/81 (2006.01), *C12N 9/24* (2006.01),
A61K 39/00 (2006.01)

(72) Inventeurs/Inventors:
 DEROO, TOM MARIA, BE;
 MIN JOU, WILLY ALFONS, BE;
 FIER, WALTER CHARLES, BE

(73) Propriétaire/Owner:
 VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR
 BIOTECHNOLOGIE, BE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : VACCIN CONTRE LA GRIPPE
 (54) Title: INFLUENZA VACCINE

(57) Abrégé/Abstract:

The present invention relates to a recombinant neuraminidase to be obtained by culturing in a suitable culture medium host cells which are transformed with a neuraminidase expression vector or infected with a virus which is transformed with a neuraminidase expression vector, wherein the expression vector comprises at least a part of the coding region of a neuraminidase gene of an influenza virus minus the region which codes for the membrane anchor, or a modified version thereof, preceded in phase by a signal sequence; and isolating the expression product neuraminidase from the culture medium. The invention further relates to a vaccine in which the recombinant neuraminidase is applied, and methods for manufacturing and purifying thereof.